論文業績

2023年

  1. Rizk DV, Rovin BH, Zhang H, Kashihara N, Maes B, Trimarchi H, Perkovic V, Meier M, Kollins D, Papachristofi O, Charney A, Barratt J.：Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study. Kidney Int Rep. 2023;8(5):968-979.
  2. Kishi S, Nagasu H, Kidokoro K, Kashihara N.：Oxidative stress and the role of redox signalling in chronic kidney disease. Nat Rev Nephrol. 2023.20(2):101-119.
  3. Kidokoro K, Kadoya H, Cherney DZI, Kondo M, Wada Y, Umeno R, Kishi S, Nagasu H, Nagai K, Suzuki T, Sasaki T, Yamamoto M, Kanwar YS, Kashihara N.：Insights into the Regulation of GFR by the Keap1-Nrf2 Pathway. Kidney360. 2023;4(10):1454-1466.
  4. Kurasawa S, Yasuda Y, Kato S, Maruyama S, Okada H, Kashihara N, Narita I, Wada T, Yamagata K; REACH-J CKD collaborators.：Relationship between the lower limit of systolic blood pressure target and kidney function decline in advanced chronic kidney disease: an instrumental variable analysis from the REACH-J CKD cohort study. Hypertens Res. 2023;46(11):2478-2487.
  5. Nangaku M, Takama H, Ichikawa T, Mukai K, Kojima M, Suzuki Y, Watada H, Wada T, Ueki K, Narita I, Kashihara N, Kadowaki T, Hase H, Akizawa T.：Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study. Nephrol Dial Transplant. 2023;38(5):1204-1216.
  6. Asahina Y, Sakaguchi Y, Kajimoto S, Hattori K, Oka T, Kaimori JY, Kashihara N, Isaka Y.：A Randomized Controlled Trial of Whole-Body Vibration on Gait Ability and Balance among Older Hemodialysis Patients. Clin J Am Soc Nephrol. 2023;18(1):84-90.
  7. Yanagita M, Muto S, Nishiyama H, Ando Y, Hirata S, Doi K, Fujiwara Y, Hanafusa N, Hatta T, Hoshino J, Ichioka S, Inoue T, Ishikura K, Kato T, Kitamura H, Kobayashi Y, Koizumi Y, Kondoh C, Matsubara T, Matsubara K, Matsumoto K, Okuda Y, Okumura Y, Sakaida E, Shibagaki Y, Shimodaira H, Takano N, Uchida A, Yakushijin K, Yamamoto T, Yamamoto K, Yasuda Y, Oya M, Okada H, Nangaku M, Kashihara N.：Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022. Clin Exp Nephrol. 2023.28(2):85-122.
  8. Kanda E, Epureanu BI, Adachi T, Kashihara N.：Machine-learning-based Web system for the prediction of chronic kidney disease progression and mortality. PLOS Digit Health. 2023;2(1):e0000188.
  9. Zhang H, Rizk DV, Perkovic V, Maes B, Kashihara N, Rovin B, Trimarchi H, Sprangers B, Meier M, Kollins D, Papachristofi O, Milojevic J, Junge G, Nidamarthy PK, Charney A, Barratt J.：Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy. Kidney Int. 2023:S0085-2538(23)00754-8.
  10. Sugawara Y, Kanda E, Ohsugi M, Ueki K, Kashihara N, Nangaku M.：eGFR slope as a surrogate endpoint for end-stage kidney disease in patients with diabetes and eGFR > 30 mL/min/1.73 m2 in the J-DREAMS cohort. Clin Exp Nephrol. 2023;28(2):144-152.
  11. Itano S, Kanda E, Nagasu H, Nangaku M, Kashihara N.：eGFR slope as a surrogate endpoint for clinical study in early stage of chronic kidney disease: from The Japan Chronic Kidney Disease Database. Clin Exp Nephrol. 2023;27(10):847-856.
  12. Okuda Y, Ito S, Kashihara N, Shikata K, Nangaku M, Wada T, Sawanobori T, Taguri M.：The renoprotective effect of esaxerenone independent of blood pressure lowering: a post hoc mediation analysis of the ESAX-DN trial. Hypertens Res. 2023;46(2):437-444.
  13. Sugawara Y, Hirakawa Y, Nagasu H, Narita A, Katayama A, Wada J, Shimizu M, Wada T, Kitamura H, Nakano T, Yokoi H, Yanagita M, Goto S, Narita I, Koshiba S, Tamiya G, Nangaku M, Yamamoto M, Kashihara N.：Genome-wide association study of the risk of chronic kidney disease and kidney-related traits in the Japanese population: J-Kidney-Biobank.: J Hum Genet. 2023;68(2):55-64.
  14. Ikeda A, Fujii M, Ohno Y, Godai K, Li Y, Nakamura Y, Yabe D, Tsushita K, Kashihara N, Kamide K, Kabayama M.：Effect of the Diabetic Nephropathy Aggravation Prevention Program on medical visit behavior in individuals under the municipal national health insurance.: J Diabetes Investig. 2023;14(6):782-791.
  15. Yano Y, Nagasu H, Kanegae H, Nangaku M, Hirakawa Y, Sugawara Y, Nakagawa N, Wada J, Sugiyama H, Nakano T, Wada T, Shimizu M, Suzuki H, Komatsu H, Nakashima N, Kitaoka K, Narita I, Okada H, Suzuki Y, Kashihara N.：Kidney outcomes associated with haematuria and proteinuria trajectories among patients with IgA nephropathy in real-world clinical practice: The Japan Chronic Kidney Disease Database.: Nephrology (Carlton). 2023;29(2):65-75.
  16. Fujii M, Ohno Y, Ikeda A, Godai K, Li Y, Nakamura Y, Yabe D, Tsushita K, Kashihara N, Kamide K, Kabayama M.：Current evidence and perspectives for hypertension management in Asia
    Current status of the rapid decline in renal function due to diabetes mellitus and its associated factors: analysis using the National Database of Health Checkups in Japan.:         Hypertens Res. 2023;46(5):1075-1089.
  17. Li Y, Fujii M, Ohno Y, Ikeda A, Godai K, Nakamura Y, Akagi Y, Yabe D, Tsushita K, Kashihara N, Kamide K, Kabayama M.：Lifestyle factors associated with a rapid decline in the estimated glomerular filtration rate over two years in older adults with type 2 diabetes-Evidence from a large national database in Japan.: PLoS One. 2023;18(12):e0295235.
  18. Hirano A, Kadoya H, Yamanouchi Y, Kishi S, Sasaki T, Kashihara N.：IL-1β may be an indicator of peritoneal deterioration after healing of peritoneal dialysis-associated peritonitis.: BMC Nephrol. 2023;24(1):374.
  19. Hajime Nagasu, Atsuyuki Tokuyama, Eiichiro Kanda, Seiji Itano, Seiji Kishi, Tamaki Sasaki, Naoki Kashihara.：The Impact of Potassium Binders on Mortality in Patients with Hyperkalemia.: Kidney Dial dialysis. 2023;3(3):244-254.

2022年

  1. Takasu M, Kadoya H, Yamanouchi Y, Nojima Y, Yamamoto T, Itano S, Nakata M, Sasaki T, Kashihara N.：A case of pleuroperitoneal communication during long-term steroid therapy for dermatomyositis. Perit Dial Int. 2022;42(4):434-436.
  2. Maruyama Y, Araki M, Kidokoro K, Sogawa Y, Yoshinaga K, Mitsui Y, Sadahira T, Wada K, Watanabe M, Watanabe T, Kashihara N, Nasu Y.：Evaluation of Neutrophil Dynamics Change by Protective Effect of Tadalafil After Renal Ischemia/Reperfusion Using In Vivo Real-time Imaging. Transplantation. 2022;106(2):280-288.
  3. Yano Y, Kanegae H, Node K, Mizuno A, Nishiyama A, Rakugi H, Itoh H, Kitaoka K, Kashihara N, Ikeno F, Tsuji I, Okada K.：The associations of the national health and productivity management program with corporate profits in Japan. Epidemiol Health. 2022;23.
  4. Okuda Y, Ito S, Kashihara N, Shikata K, Nangaku M, Wada T, Sawanobori T, Taguri M.：The renoprotective effect of esaxerenone independent of blood pressure lowering: a post hoc mediation analysis of the ESAX-DN trial. Hypertens Res. 2022;13.
  5. James G, Garcia Sanchez JJ, Carrero JJ, Kumar S, Pecoits-Filho R, Heerspink HJL, Nolan S, Lam CSP, Chen H, Kanda E, Kashihara N, Arnold M, Kosiborod MN, Lainscak M, Pollock C, Wheeler DC.：Low Adherence to Kidney Disease: Improving Global Outcomes 2012 CKD Clinical Practice Guidelines Despite Clear Evidence of Utility. Kidney Int Rep. 2022;8;7(9):2059-2070.
  6. Nangaku M, Takama H, Ichikawa T, Mukai K, Kojima M, Suzuki Y, Watada H, Wada T, Ueki K, Narita I, Kashihara N, Kadowaki T, Hase H, Akizawa T.：Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: Design and baseline characteristics of AYAME study. Nephrol Dial Transplant. 2022;24.
  7. Jongs N, Chertow GM, Greene T, McMurray JJV, Langkilde AM, Correa-Rotter R, Kashihara N, Rossing P, Sjöström CD, Stefánsson BV, Toto RD, Wheeler DC, Heerspink HJL; DAPA-CKD Trial Committees and Investigators.：Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD. J Am Soc Nephrol. 2022;17.
  8. Kimura T, Yamamoto R, Yoshino M, Sakate R, Imai E, Maruyama S, Yokoyama H, Sugiyama H, Nitta K, Tsukamoto T, Uchida S, Takeda A, Sato T, Wada T, Hayashi H, Akai Y, Fukunaga M, Tsuruya K, Masutani K, Konta T, Shoji T, Hiramatsu T, Goto S, Tamai H, Nishio S, Nagai K, Yamagata K, Yasuda H, Ichida S, Naruse T, Nishino T, Sobajima H, Akahori T, Ito T, Terada Y, Katafuchi R, Fujimoto S, Okada H, Mimura T, Suzuki S, Saka Y, Sofue T, Kitagawa K, Fujita Y, Mizutani M, Kashihara N, Sato H, Narita I, Isaka Y.：Deep learning analysis of clinical course of primary nephrotic syndrome: Japan Nephrotic Syndrome Cohort Study (JNSCS). Clin Exp Nephrol. 2022;12.
  9. Sato R, Matsuzawa Y, Ogawa H, Kimura K, Tsuboi N, Yokoo T, Okada H, Konishi M, Kirigaya J, Fukui K, Tsukahara K, Shimizu H, Iwabuchi K, Yamada Y, Saka K, Takeuchi I, Kashihara N, Tamura K.：Chronic kidney disease and clinical outcomes in patients with COVID-19 in Japan. Clin Exp Nephrol. 2022;26(10):974-981.
  10. Sugawara Y, Hirakawa Y, Mise K, Kashiwabara K, Hanai K, Yamaguchi S, Katayama A, Onishi Y, Yoshida Y, Kashihara N, Matsuyama Y, Babazono T, Nangaku M, Wada J.：Analysis of inflammatory cytokines and estimated glomerular filtration rate decline in Japanese patients with diabetic kidney disease: a pilot study. Biomark Med. 2022;16(10):759-770.
  11. Nakagawa N, Maruyama S, Kashihara N, Narita I, Isaka Y.：New-onset and relapse of nephrotic syndrome following COVID-19 vaccination: a questionnaire survey in Japan. Clin Exp Nephrol. 2022 Sep;26(9):909-916. doi: 10.1007/s10157-022-02231-y. Epub 2022;15.
  12. Shikata K, Ito S, Kashihara N, Nangaku M, Wada T, Okuda Y, Sawanobori T, Sugimoto K.：Reduction in the magnitude of serum potassium elevation in combination therapy with esaxerenone (CS-3150) and sodium-glucose cotransporter 2 inhibitor in patients with diabetic kidney disease: Subanalysis of two phase Ⅲ studies. J Diabetes Investig. 2022;13(7):1190-1202.
  13. Handa M, Kato S, Sakurai G, Yabe T, Demura S, Takeshita Y, Kanamori T, Nakano Y, Shinmura K, Yokogawa N, Kashihara N, Yahata T, Takamura T, Tsuchiya H.：The Prevalence of Locomotive Syndrome and its Associated Factors in Patients With Type 2 Diabetes Mellitus. Mod Rheumatol. 2022;2.
  14. Zheng J, Zhang Y, Rasheed H, Walker V, Sugawara Y, Li J, Leng Y, Elsworth B, Wootton RE, Fang S, Yang Q, Burgess S, Haycock PC, Borges MC, Cho Y, Carnegie R, Howell A, Robinson J, Thomas LF, Brumpton BM, Hveem K, Hallan S, Franceschini N, Morris AP, Köttgen A, Pattaro C, Wuttke M, Yamamoto M, Kashihara N, Akiyama M, Kanai M, Matsuda K, Kamatani Y, Okada Y, Walters R, Millwood IY, Chen Z, Davey Smith G, Barbour S, Yu C, Åsvold BO, Zhang H, Gaunt TR. Int J Epidemiol.：The Prevalence of Locomotive Syndrome and its Associated Factors in Patients With Type 2 Diabetes Mellitus. 2022;6;50(6):1995-2010.
  15. Kitani T, Kidokoro K, Nakata T, Kirita Y, Nakamura I, Nakai K, Yagi-Tomita A, Ida T, Uehara-Watanabe N, Ikeda K, Yamashita N, Humphreys BD, Kashihara N, Matoba S, Tamagaki K, Kusaba T.：Kidney vascular congestion exacerbates acute kidney injury in mice. Kidney Int. 2022;101(3):551-562.
  16. Matsuzaki K, Aoki R, Nihei Y, Suzuki H, Kihara M, Yokoo T, Kashihara N, Narita I, Suzuki Y.：Correction to: Gross hematuria after SARS-CoV-2 vaccination: questionnaire survey in Japan. Clin Exp Nephrol. 2022 Apr;26(4):323-324. doi: 10.1007/s10157-021-02164-y. Erratum for: Clin Exp Nephrol. 2022;26(4):316-322.
  17. Ohya Y, Kario K, Itoh H, Nishiyama A, Ishimitsu T, Ichihara A, Kai H, Kashihara N, Katsuya T, Miura K, Mukoyama M, Nakamura S, Node K, Ohishi M, Saito S, Shibata H, Shimosawa T, Tamura K, Toyoda K, Ali MAM, Chia YC, Constantine G, Erwinanto E, Ihm SH, Kao HL, Van Minh H, Narasingan SN, Ona DID, Siddique S, Sukonthasarn A, Teo BW, Unurjargal T, Wang JG, Wang TD, Raukgi H.：Statement of the Asian Hypertension Society Network: the Okinawa Declaration on the unity of hypertension societies in Asian countries and regions to overcome hypertension and hypertension-related diseases. Hypertens Res. 2022 Jan;45(1):1-2. doi: 10.1038/s41440-021-00781-4. Epub 2021;9.
  18. Nagashima M, Kawakami M, Hayashi M, Kumagai R, Kasuya F, Yoshida I, Kashihara N, Morita K, Yamada K, Fujiwara T, Kitamura K, Yoshida H, Chiba T, Sadamasu K.：RNA Detection Using RT-qPCR and Non-Isolation of SARS-CoV-2 in Concentrated Wastewater (June-August 2020, Tokyo). Jpn J Infect Dis. 2022;24;75(2):212-215.

2021年

  1. Yamamoto T, Kadoya H, Urabe E, Itano S, Sasaki T, Kashihara N：A rare case of amyloid light-chain amyloidosis with bilateral perirenal hematoma shortly after initiation of peritoneal dialysis. CEN Case Rep. 2021 Jan 7.
  2. Tokuyama A, Kanda E, Itano S, Kondo M, Wada Y, Kadoya H, Kidokoro K, Nagasu H, Sasaki T, Kashihara N：Effect of zinc deficiency on chronic kidney disease progression and effect modification by hypoalbuminemia. PLoS One. 2021 May 11;16(5):e0251554.
  3. Ohsawa R, Kadoya H, Obata A, Obata T, Tokuyama A, Sasaki T, Kashihara N, Kaneto H：Renal cell carcinoma sharply captured by imaging technology at an early stage in a hemodialysis patient: Usefulness of noninvasive monochrome superb microvascular imaging. Hemodial Int. 2021 Mar 29.
  4. Nishimura K, Taguchi K, Kishi S, Brooks CR, Ochi A, Kadoya H, Ikeda Y, Miyoshi M, Tamaki M, Abe H, Aihara KI, Kashihara N, Nagai K：Dual disruption of eNOS and ApoE gene accelerates kidney fibrosis and senescence after injury. Biochem Biophys Res Commun. 2021 Jun 4;556:142-148.
  5. Desposito D, Schiessl IM, Gyarmati G, Riquier-Brison A, Izuhara A, Kadoya H, Der B, Shroff UN, Hong YK, Peti-Peterdi J：Serial intravital imaging captures dynamic and functional endothelial remodeling with single-cell resolution. JCI Insight. 2021 Apr 13;123392.
  6. Tokuyama A, Kadoya H, Obata A, Obata T, Sasaki T, Kashihara N：Roxadustat and thyroid-stimulating hormone suppression. Clin Kidney J. 2021 Jan 20;14(5):1472-1474.
  7. Maruyama Y, Araki M, Kidokoro K, Sogawa Y, Yoshinaga K, Mitsui Y, Sadahira T, Wada K, Watanabe M, Watanabe T, Kashihara N, Nasu Y：Evaluation of Neutrophil Dynamics Change by Protective Effect of Tadalafil After Renal Ischemia/Reperfusion Using In Vivo Real-time Imaging. Transplantation.Apr 27,2021.
  8. Nishiwaki H, Niihata K, Shimizu S, Shibagak Y, Yamamoto R , Nitta K, Tsukamoto T, Uchida S, Takeda A,  Okada H, Narita I, Isaka Y, Kurita N : Japan Nephrotic Syndrome Cohort Study group：Incidence and factors associated with prescribing renin-angiotensin-system inhibitors in adult idiopathic nephrotic syndrome: A nationwide cohort study. J Clin Hypertens (Greenwich). 2021 May;23(5):999-1007.

受賞

2023年

川崎医科大学　守分記念賞　長洲　一
第7回ポドサイト研究会　最優秀演題賞　城所　研吾
第13回腎不全研究会　特別奨励賞　高須　将伸
第45回日本高血圧学会総会　若手優秀ポスター発表賞　岩倉　主
第53回日本腎臓学会西部学術大会　優秀演題賞　仙田寛武

2022年

Japan Kidney Council 2022　奨励賞　高須　将伸
川崎医学会賞　川崎医学会誌論文賞　近藤　恵
日本腎臓学会　感謝状　柏原　直樹

2021年

第29回中国腎不全研究協会学術集会　優秀演題賞　高須　将伸
川崎医科大学附属病院　病院長より　感謝状　長洲　一
川崎医科大学附属病院　病院長より　感謝状　城所　研吾
日本透析医学会奨励賞　角谷　裕之